Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19

Abstract

Background: Anti-SARS-CoV-2 virus antibody levels in convalescent plasma (CP), which may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported. Results: A total of eight donors were considered for enrollment; two of them were excluded because of ineligible routine check. Of the six remaining participants, five samples were tested weakly positive by the IgM ELISA. Meanwhile, high titers of IgG were observed in five samples. The patient treated with CP did not require mechanical ventilation 11 days after plasma transfusion, and was then transferred to a general ward. Conclusions: Our serological findings in convalescent plasma from recovered patients may help facilitate understanding of the SARS-CoV-2 infection and establish CP donor screening protocol in COVID-19 outbreak. Methods: Anti-SARS-CoV-2 antibodies including IgM and IgG were measured by two enzyme-linked immunosorbent assays (ELISA) in convalescent plasma from six donors who have recovered from coronavirus disease 2019 (COVID-19) in Nanjing, China. CP was also utilized for the treatment of one severe COVID-19 patient.

Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines

“…In another CP evaluation study, 6 COVID-19 positive patients (tested by IgM ELISA) were given the therapy. After 11 days of CP transfusion, these patients did not need ventilator support ( Zhang L. et al., 2020 ), which is indicative of the positive response of CP in COVID-19 treatment.…”

Coronavirus Pandemic—Therapy and Vaccines

“…Convalescent plasma has previously been used successfully as post-exposure prophylaxis and/or treatment of SARS and MERS [166]. In the context of COVID-19, in a case study, a patient with severe COVID-19 was treated with convalescent plasma from six donors [167]. The anti-SARS-CoV IgM responses from the convalescent plasma were weak, but high titers of IgG were obtained.…”

COVID-19 in Kidney Transplantation: Epidemiology, Management Considerations, and the Impact on Kidney Transplant Practice

“… 26 In addition, emerging data suggest some efficacy for convalescent sera transfusions for patients with serious COVID-19 infections. 27 - 31 Data on seroconversion among immunosuppressed kidney transplant patients are not available at this time.…”

“…Very early data from the general population suggest some efficacy for convalescent sera transfusions for patients with serious COVID-19 infections, although no such data are available yet for KTRs or other immunosuppressed patients. 27 - 31 …”